본문 바로가기

A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
Archives of Pharmacal Research37(10) · pp.1308 · 2014
피인용
Web of Science 17KCI 2
JCR IF
JCR 2013 1.751
ISSN
0253-6269

저자

  1. 이오영제1저자한양대학교
  2. 강대환부산대학교
  3. 이동호서울대학교
  4. 정일권순천향대학교
  5. 장재영경희대학교
  6. 김진일가톨릭대학교
  7. 조진웅전주예수병원
  8. 유종선전남대학교
  9. 이강문가톨릭대학교
  10. 김경오가천대학교
  11. 최명규가톨릭대학교
  12. 이상우고려대학교
  13. 이수택전북대학교
  14. 김태오인제대학교
  15. 신영운인하대학교
  16. 설상영교신저자인제대학교

초록

Misoprostol is reported to prevent non-steroidal anti-inflammatory drug (NSAID)-associated gastroduodenal complications. There is, however, limited information regarding the efficacy of DA-9601 in this context. We performed a comparative study on the relative efficacy of DA-9601 and misoprostol for prevention of NSAID-associated complications. In this multicenter, double-blinded, active-controlled, stratified randomized, parallel group, non-inferiority trial, 520 patients who were to be treated with an NSAID (aceclofenac, 100 mg, twice daily) over a 4-week period were randomly assigned to groups for coincidental treatment with DA-9601 (60 mg, thrice daily) (236 patients for full analysis) or misoprostol (200 mu g, thrice daily) (242 patients for full analysis). A total of 236 patients received DA-9601 and 242 received misoprostol. The primary endpoint was the gastric protection rate, and secondary endpoints were the duodenal protection rate and ulcer incidence rate. Endpoints were assessed by endoscopy after the 4-week treatment period. Drug-related adverse effects, including gastrointestinal (GI) symptoms, were also compared. At week 4, the gastric protection rates with DA-9601 and misoprostol were 81.4 % (192/236) and 89.3 % (216/242), respectively. The difference between the groups was -14.2 %, indicating non-inferiority of DA-9601 to misoprostol. Adverse event rates were not different between the two groups; however, the total scores for GI symptoms before and after administration were significantly lower in the DA-9601 group than in the misoprostol group (-0.2 +/- A 2.8 vs 1.2 +/- A 3.2; p < 0.0001). DA-9601 is as effective as misoprostol in preventing NSAID-associated gastroduodenal complications, and has a superior adverse GI effect profile.

키워드

DA-9601(Stilen (R))MisoprostolNSAID-associatedGastroduodenal injuryNONSTEROIDAL ANTIINFLAMMATORY DRUGSPEPTIC-ULCER DISEASEHELICOBACTER-PYLORI INFECTIONGASTRIC EPITHELIAL-CELLSPLACEBO-CONTROLLED TRIALLONG-TERM USERSDOUBLE-BLINDARTEMISIA-ASIATICAGASTROINTESTINAL COMPLICATIONSOXIDATIVE STRESS

식별자

WoS UID
000342441800009
KCI
ART001921312